Cargando…

Prognostic impact of adjuvant chemotherapy treatment intensity for ovarian cancer

OBJECTIVE: We aimed to investigate the prognostic impact of duration of first-line chemotherapy administration in patients with epithelial ovarian cancer (EOC). METHODS: Chemotherapy records were abstracted from the electronic medical record. Patients with on-time completion (105 days) were compared...

Descripción completa

Detalles Bibliográficos
Autores principales:	Starbuck, Kristen D., Szender, J. Brian, Duncan, William D., Morrell, Kayla, Etter, John Lewis, Zsiros, Emese, Odunsi, Kunle, Moysich, Kirsten, Eng, Kevin H.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2018
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6231633/ https://www.ncbi.nlm.nih.gov/pubmed/30418985 http://dx.doi.org/10.1371/journal.pone.0206913

Ejemplares similares

Paternal lineage early onset hereditary ovarian cancers: A Familial Ovarian Cancer Registry study
por: Eng, Kevin H., et al.
Publicado: (2018)

Transmission of X-linked Ovarian Cancer: Characterization and Implications
por: Etter, John Lewis, et al.
Publicado: (2020)

Ultrarestrictive Opioid Prescription Protocol for Pain Management After Gynecologic and Abdominal Surgery
por: Mark, Jaron, et al.
Publicado: (2018)

Whole‐exome sequencing of ovarian cancer families uncovers putative predisposition genes
por: Zhu, Qianqian, et al.
Publicado: (2019)

Evaluation of satisfaction with work–life balance among U.S. Gynecologic Oncology fellows: A cross-sectional study
por: Szender, J. Brian, et al.
Publicado: (2016)

History of thyroid disease and survival of ovarian cancer patients: results from the Ovarian Cancer Association Consortium, a brief report
por: Minlikeeva, Albina N, et al.
Publicado: (2017)

Estrogen Receptor-Beta2 (ERβ2)–Mutant p53–FOXM1 Axis: A Novel Driver of Proliferation, Chemoresistance, and Disease Progression in High Grade Serous Ovarian Cancer (HGSOC)
por: Oturkar, Chetan C., et al.
Publicado: (2022)

Discovery of candidate tumor biomarkers for treatment with intraperitoneal chemotherapy for ovarian cancer
por: Seagle, Brandon-Luke L., et al.
Publicado: (2016)

Immuno-stimultory/regulatory gene expression patterns in advanced ovarian cancer
por: Eng, Kevin H., et al.
Publicado: (2015)

Clonality and antigen-specific responses shape the prognostic effects of tumor-infiltrating T cells in ovarian cancer
por: Tsuji, Takemasa, et al.
Publicado: (2020)

Quantitative global lipidomics analysis of patients with ovarian cancer versus benign adnexal mass
por: Buas, Matthew F., et al.
Publicado: (2021)

BiTE secretion by adoptively transferred stem-like T cells improves FRα+ ovarian cancer control
por: McGray, A J Robert, et al.
Publicado: (2023)

Predictors of Immunosuppressive Regulatory T Lymphocytes in Healthy Women
por: Hampras, Shalaka S., et al.
Publicado: (2012)

Mitochondrial DNA in the tumour microenvironment activates neutrophils and is associated with worse outcomes in patients with advanced epithelial ovarian cancer
por: Singel, Kelly L., et al.
Publicado: (2018)

Survival of patients with structurally-grouped TP53 mutations in ovarian and breast cancers
por: Seagle, Brandon-Luke L., et al.
Publicado: (2015)

Whole-Genome Sequencing Identifies PPARGC1A as a Putative Modifier of Cancer Risk in BRCA1/2 Mutation Carriers
por: Zhu, Qianqian, et al.
Publicado: (2022)

Induction of cell death in ovarian cancer cells by doxorubicin and oncolytic vaccinia virus is associated with CREB3L1 activation
por: Mistarz, Anna, et al.
Publicado: (2021)

Targeting myeloid cells in the tumor microenvironment enhances vaccine efficacy in murine epithelial ovarian cancer
por: Khan, Anm Nazmul H., et al.
Publicado: (2015)

PRAME expression and promoter hypomethylation in epithelial ovarian cancer
por: Zhang, Wa, et al.
Publicado: (2016)

Identification of Claudin 6-specific HLA class I- and HLA class II-restricted T cell receptors for cellular immunotherapy in ovarian cancer
por: Matsuzaki, Junko, et al.
Publicado: (2022)

Novel genetic variants in miR-191 gene and familial ovarian cancer
por: Shen, Jie, et al.
Publicado: (2010)

GEN-1 in Combination with Neoadjuvant Chemotherapy for Patients with Advanced Epithelial Ovarian Cancer: A Phase I Dose-escalation Study
por: Thaker, Premal H., et al.
Publicado: (2021)

Ovarian Cancer Spheroid Cells with Stem Cell-Like Properties Contribute to Tumor Generation, Metastasis and Chemotherapy Resistance through Hypoxia-Resistant Metabolism
por: Liao, Jianqun, et al.
Publicado: (2014)

Mitochondrial DNA sequence variants in epithelial ovarian tumor subtypes and stages
por: Aikhionbare, Felix O, et al.
Publicado: (2007)

Autologous whole-tumor antigen vaccination in combination with adoptive T cell therapy for patients with recurrent ovarian cancer
por: Kandalaft, Lana E, et al.
Publicado: (2013)

The combination of intravenous bevacizumab and metronomic oral cyclophosphamide is an effective regimen for platinum-resistant recurrent ovarian cancer
por: Barber, Emma L., et al.
Publicado: (2013)

Reprogramming antitumor immunity against chemoresistant ovarian cancer by a CXCR4 antagonist-armed viral oncotherapy
por: Komorowski, Marcin P, et al.
Publicado: (2016)

Compensatory upregulation of PD-1, LAG-3, and CTLA-4 limits the efficacy of single-agent checkpoint blockade in metastatic ovarian cancer
por: Huang, Ruea-Yea, et al.
Publicado: (2016)

On representing the prognostic value of continuous gene expression biomarkers with the restricted mean survival curve
por: Eng, Kevin H., et al.
Publicado: (2015)

Expression and Immune Responses to MAGE Antigens Predict Survival in Epithelial Ovarian Cancer
por: Daudi, Sayeema, et al.
Publicado: (2014)

Tumor-infiltrating T lymphocyte clonality predicts prognosis in human ovarian cancer
por: Tsuji, Takemasa, et al.
Publicado: (2013)

LAG3 and PD1 co-inhibitory molecules collaborate to limit CD8(+) T cell signaling and dampen antitumor immunity in a murine ovarian cancer model
por: Huang, Ruea-Yea, et al.
Publicado: (2015)

Elevated Expression of the Serine-Arginine Protein Kinase 1 Gene in Ovarian Cancer and Its Role in Cisplatin Cytotoxicity In Vitro
por: Odunsi, Kunle, et al.
Publicado: (2012)

Decreased levels of serum glutathione peroxidase 3 are associated with papillary serous ovarian cancer and disease progression
por: Agnani, Deep, et al.
Publicado: (2011)

CXCR6 by increasing retention of memory CD8(+) T cells in the ovarian tumor microenvironment promotes immunosurveillance and control of ovarian cancer
por: Muthuswamy, Ravikumar, et al.
Publicado: (2021)

Abundance of Regulatory T Cell (Treg) as a Predictive Biomarker for Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer
por: Oshi, Masanori, et al.
Publicado: (2020)

Impact of neoadjuvant chemotherapy and postoperative adjuvant chemotherapy cycles on survival of patients with advanced-stage ovarian cancer
por: Chung, Young Shin, et al.
Publicado: (2017)

Adjuvant chemotherapy
por: Glimelius, B.
Publicado: (2013)

Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer
por: Riggs, McKayla J., et al.
Publicado: (2020)

Global DNA Hypomethylation in Epithelial Ovarian Cancer: Passive Demethylation and Association with Genomic Instability
por: Zhang, Wa, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_qptmgk89uf6l9iqg4h6i3dstdv